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1Introduction
Lung cancer is a significant health problem worldwide 
and the most common cause of cancer death in the 
industrialized world [1]. In Denmark, lung cancer com-
prises 12% of all new cancer cases [2]. Survival from 
lung cancer is related to the stage of disease, and 5- year 
survival is 50% for localized lung cancer and 2% for a 
lung cancer with distant spread. Earlier diagnosis of lung 
cancer may be beneficial in allowing more lung cancer 
patients curative treatment. Danish lung cancer patients 
have lower survival than patients from comparable 
European countries [3, 4]. This can possibly be explained 
by later diagnosis of lung cancer in Denmark and research 
indicates a lower proportion of lung cancer patients in 
curable stage in Denmark compared to Norway and Sweden 
[5]. Thus, it is possible that the survival deficit in Danish 
patients may relate to processes of cancer awareness and 
diagnostic activity at the level of primary care. Delay in 
diagnosis before admission to a hospital can be due to 
either patients delaying going to the general practitioner 
(GP) (the so called patient’s interval) or the GP delaying 
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Abstract
Patterns of general practice utilization in the period before lung cancer (LC) 
diagnosis may provide new knowledge to ensure timelier and earlier diagnosis 
of LC. This study aimed to explore the prediagnostic activity in general practice 
in the year preceding LC diagnosis. The activity was compared to a matched 
comparison group. We compared LC patients with different stage, and patients 
with and without chronic obstructive pulmonary disease (COPD). Using Danish 
registers, we performed a population- based matched cohort study including 
lung cancer patients (n = 34,017) and matched comparison subjects 
(n = 340,170). During months 12 to 1 prior to diagnosis, 92.6% of LC patients 
and 88.4% of comparison subjects had one or more contacts with general prac-
tice. 13.0% of LC patients and 3.3% of comparison subjects had two or more 
X- rays. 20.8% of LC patients and 8.5% of comparison subjects had two or 
more first- time antibiotics prescriptions. The incidence rate ratio for having a 
contact to general practice was similar for LC patients with localized disease 
compared to LC patients with metastatic disease. LC patients with COPD had 
more frequent contacts, lung functions tests, X- rays, and prescriptions than 
COPD patients without lung cancer, but not as pronounced as compared to 
patients without COPD. There was a significant increase in healthcare seeking 
and diagnostic activity in the year prior to a LC diagnosis, regardless of stage 
at diagnosis. COPD may mask the symptoms of LC. This indicates the presence 
of a “diagnostic time window” and a potential for more timely diagnosis of 
LC based on clinical signs and symptoms.
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referral (doctor’s interval). This warrants scrutiny of the 
diagnostic pathway in Danish lung cancer patients.
Most lung cancer patients present with a range of 
symptoms to the GP in the months before diagnosis [6–9]. 
The symptoms, such as cough and breathlessness, are 
relatively common in the general population [10], and 
alarm symptoms for lung cancer have low- positive predic-
tive values [11]. Symptoms and signs from lung cancer 
can mimic common diseases such as chronic obstructive 
pulmonary disease (COPD), leading to a risk for delayed 
diagnosis [12].
Only a third of lung cancer patients present to GPs 
with an alarm symptom (such as prolonged coughing, 
hemoptysis, or weight loss) [12] which is the entrance 
criterion for the urgent referral route for lung cancer. 
The PPVs for such symptoms are, depending on the 
patient’s age, between 1% and 4.5%.
Consequently, only 25% of all lung cancer patients are 
diagnosed through this route [12, 13]. There seems to 
be a need for other referral options for this group of 
patients. For persons who were later diagnosed with lung 
cancer we quantified the prediagnostic activity in general 
practice along with a matched comparison group, and 
we compared the activity between lung cancer patients 
with different stage, and between lung cancer patients 
with and without COPD.
Methods
Study design and study population
In Denmark (5.6 million inhabitants), 4560 new lung 
cancer cases are diagnosed yearly. The age- standardized 
(World standard population) lung cancer incidence rates 
for men and women were 49.9 and 36.7, respectively, 
with a 1.4% decrease for men and 0.1% increase for 
women during the study period. We performed a 
population- based matched cohort study using register data. 
Information was collected from nationwide registers at 
individual level using the unique civil registration number 
assigned to all Danish residents [14]. In Denmark, GPs 
are gatekeepers to the rest of the health care system and 
98% of citizens are listed with a general practice and 
have free access. GPs are remunerated based on a mixed 
capitation and fee- for- service (25/75%) which ensures 
complete registration of their services.
Lung cancer patients
Patients diagnosed with lung cancer (according to the 
International Classification of Diseases, ICD- 10 C34) from 
1 January 2003 to 31 December 2012 (n = 36,342) in 
Denmark were identified in the Danish Cancer Registry 
(DCR) and the Danish Lung Cancer Registry (DLCR). 
The DCR is a national register of all Danish cancer patients 
and holds information on date of diagnosis (ICD- 10), 
anatomical site, morphology, and stage. If a patient devel-
ops more than one primary cancer, each cancer is reg-
istered as a separate record. In the DCR, information 
about tumor stage at diagnosis is provided by a multi-
disciplinary team decision, it contains both cTNM and 
pTNM if available. Reporting to the DCR became manda-
tory in 1987 [15]. The DLCR was established in 2001. 
It contains clinical information about Danish lung cancer 
patients such as lung function, smoking history, and stage, 
which are combined with data on cancer treatment and 
follow- up. In the DLCR, information about tumor stage 
at diagnosis is provided by a multidisciplinary team deci-
sion with one TNM stage (which can be either cTNM 
or pTNM). Since 2003, the DLCR includes data on more 
than 90% of all lung cancer cases in Denmark [16].
Lung cancer patients were excluded from the analyses if 
they had an incorrect civil registration number (n = 398 
[1.1%]), had lived outside Denmark at some point during 
the 12 months preceding the diagnosis (n = 670 [1.8%]) 
or were not listed with a general practice (n = 672 [1.8%]). 
We furthermore excluded 163 (0.5%) patients aged less than 
40 years and 202 (0.6%) patients aged more than 90 years.
The comparison cohort
Ten comparison subjects were selected for each patient. 
They matched the lung cancer patient on year of birth, 
gender and were listed with the same general practice as 
the lung cancer patients at time of diagnosis (index date). 
As for patients, these persons were ineligible if they had 
been living outside Denmark at some point during the 
12 months before the index date. Patients and comparison 
subjects could have no record of any cancer in the DCR 
at the time of the index date (except nonmelanoma skin 
cancer).
We excluded 220 (0.6%) lung cancer patients which 
we were not able to match with comparison subjects. 
This left 34,017 lung cancer patients for analysis.
Prediagnostic activity
In order to estimate the prediagnostic health care activity 
for patients, we selected a range of diagnostic test or 
treatments made in general practice that a GP would use 
if a patient presented with pulmonary symptoms.
Data sources
Information about general practice enrolment was available 
from the Patient List Register, which is an administrative 
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database that holds information on which general practice 
each person is listed with at any given time.
Activity in general practice
The Danish National Health Service Registry (HSR) was 
used to gather information about contacts in general prac-
tice [17]. Face- to- face consultations, home visits and tel-
ephone contacts during daytime were included. HSR was 
also used to obtain information about numbers and dates 
of lung function tests performed in general practice. The 
tests included: extended lung function test with spirometry 
(activity code: 7113), double lung function test for exercise- 
induced asthma (7121) and peak flow (7183).
The prescriptions of medicines for respiratory diseases 
and infections were collected from the Danish National 
Prescription Registry (DNPR) [18]. The products included: 
adrenergic (ATC: R03AC, R03CC), adrenergic and glu-
cocorticoids (RO3AK) anticholinergics (R03BB), theophyl-
line (R03DA), glucocorticoids, systemic (H02AB), 
leukotrienes (R03DC), glucocorticoids, inhalation (R03BA), 
penicillin (J01C), and tetracycline (J01AA). These medicines 
are all available by prescription only.
In the analyses we focused on new or first- time pre-
scriptions redeemed and lung function test performed in 
the 12 months before diagnosis; that is, that it was only 
included if there had been no prescription redeemed or 
lung function test performed in the period between 12 
and 36 months before lung cancer diagnosis.
Data on radiology procedures were obtained from the 
HSR and the Danish National Patient Registry (NPR) 
[19]. The NPR is a national population- based database 
containing admission and discharge dates, combined with 
diagnoses classified according to ICD- 10.
COPD diagnoses
We identified patients as having COPD if they in the 
period 12–36 months before lung cancer diagnosis had 
either at least two redeemed prescriptions of relevant 
medicine, an inpatient visit (See appendix, Table 1, for 
the ICD10 codes for the inpatient visit) or at least two 
lung function tests performed in general practice [20]. 
The medicine included the following ACT codes: R03AC, 
R03AK, R03BA, R03BB, R03CC, R03DA, R03DC, and 
V03AN01 (oxygen).
Lung cancer stage
Information about stage was obtained from DCR and the 
DLCR. The pTNM was used if available. If the two reg-
istries differed in regard to the TNM stage, the DLCR 
was used. Stage at diagnosis was dichotomized into local 
and advanced disease. A cut- point between stage IIB and 
IIIA was chosen since a previous study has documented 
a significant difference in mortality between these two 
stages [21]. If any of the T or N values were missing, we 
categorized SCLC as limited if the tumor was M0 and as 
extensive if the tumor was M1 regardless of the values, 
known or unknown, of other components. We categorized 
NSCLC as advanced if the TNM stage included values of 
T4, N3, or M1, regardless of other components [22].
Characteristics of study population
Demographic and socioeconomic information was collected 
from Statistics Denmark. This included country of origin 
categorized into “Danish”, “Immigrant/descendant from 
a Western country”, or “Immigrant/descendant from a 
non- Western country”. Marital status 12 months prior to 
the diagnosis date was categorized into “living alone” or 
“cohabitating”. Data on taxable income were extracted 
for the calendar year preceding the diagnosis date and 
categorized into three groups using the OECD- modified 
scale: “Low” (the lowest 20%), “Middle” (the middle 50%), 
and “High” (the highest 30%)[23]. The highest attained 
level of education was categorized into “Basic”, “Short”, 
“Long”, and “Unknown” according to the international 
Standard Classification of Education [24]. The Charlson 
Comorbidity Index (CCI) was used to account for comor-
bidity [25]. The CCI was calculated on the basis of diag-
noses registered in the NPR in a 10- year- period preceding 
the 12 months prior to the diagnosis date. We grouped 
the CCI into “Low” (CCI score = 0), “Moderate” (CCI 
score = 1–2), and “severe” (CCI score ≥3).
Statistical analysis
Odds ratios (ORs) for having a contact, a radiograph, a 
lung function test or a medicine prescription were cal-
culated using conditional logistic regression, taking account 
of the matched design. Unconditional logistic regression 
analyses were made to compare lung cancer patient with 
local and advanced stage, and lung cancer patients with 
and without COPD. A negative binomial regression model 
applying cluster robust variance at practice level was used 
to calculate incidence rate ratios (IRRs) for comparisons 
of monthly rates of contacts, lung function tests, X- rays, 
and prescriptions between lung cancer patients and the 
comparison group in the year before diagnosis.
Analyses were performed separately for each sex because 
of known differences in the use of general practice among 
men and women [26, 27]. However, the estimates did 
not differ meaningfully between men and women, and 
are therefore presented combined (See appendix, Table 2 
and Table 3, for separate analyses).
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All analyses were adjusted for socioeconomic, demo-
graphic variables, age, and comorbidity. Data were analyzed 
using the statistical software Stata 13.0 (StataCorp LP, 
Texas, TX).
Ethics
The study was approved by the Danish Data Protection 
Agency (j.no. 2009- 41- 3471). 
Results
The study included 34,017 lung cancer patients and 340,170 
comparison subjects. The study subjects were listed with 
2676 general practices. Among the lung cancer patients 
18.6% had localized disease (stage IA–IIB), 81.4% had 
advanced disease (stage IIIA–IV), and 0.7% of cases had 
no information on stage. A total of 7551 lung cancer 
patients (22.2%) were identified as having COPD compared 
to 11.9% in the comparison group.
The patients and comparison subjects differed according 
to socio- demographic variables and comorbidity (Table 1). 
Lung cancer patients were more likely to be living alone 
and had lower income, lower education level, and higher 
comorbidity score. The mean age at diagnosis was 68 
and 69 years for women and men, respectively.
During months 12 to 1 prior to diagnosis (i.e., omitting 
the last month before diagnosis), 92.6% of lung cancer 
Table 1. Characteristics of the 34,017 incident lung cancer patients and the 340,170 comparison subjects.
Women Men All
Lung cancer 
patients
Comparison 
subjects
Lung cancer 
patients
Comparison 
subjects
Lung cancer 
patients
Comparison 
subjects
Total 15,655 46.0% 156,550 46.0% 18,362 54.0% 183,620 54.0% 34,017 340,170
Age
40–52 1317 8.4% 13,129 8.4% 1000 5.5% 10,018 5.5% 2317 6.8% 23,147 6.8%
53–64 4514 28.8% 45,175 28.9% 5001 27.2% 50,099 27.3% 9515 28.0% 95,274 28.0%
65–76 6432 41.1% 64,371 41.1% 8074 44.0% 80,840 44.0% 14,506 42.6% 145,211 42.6%
77–90 3392 21.7% 33,875 21.6% 4287 23.3% 42,663 23.2% 7679 22.6% 76,538 22.6%
Country of origin
Danish 15,172 96.9% 148,764 95.0% 17,550 95.6% 175,226 95.4% 32,722 96.2% 323,990 95.2%
I mmigrant/
descendant 
(Western)
357 2.3% 4348 2.8% 410 2.2% 4115 2.2% 767 2.3% 8464 2.5%
Immigrant/
descendant 
(non- Western)
126 0.8% 3438 2.2% 402 2.2% 4278 2.4% 528 1.5% 7716 2.3%
Marital status
Married/cohabitating 6799 43.4% 77,584 49.5% 10,780 58.7% 118,393 64.5% 17,579 51.7% 195,977 57.6%
Living alone 7157 45.7% 61,976 39.6% 5664 30.9% 46,046 25.1% 12,821 37.7% 108,022 31.8%
Unknown 1699 10.9% 16,990 10.9% 1918 10.4% 19,181 10.4% 3617 10.6% 36,171 10.6%
Education
Basic 9285 59.3% 75,282 48.1% 7942 43.3% 67,866 37.0% 17,227 50.6% 143,148 42.1%
Short 4573 29.2% 53,011 33.9% 8063 43.9% 82,883 45.1% 12,636 37.1% 135,894 40.0%
Long 1267 8.1% 22,220 14.2% 1463 8.0% 25,022 13.6% 2730 8.0% 47,242 13.9%
Unknown 530 3.4% 6037 3.8% 894 4.8% 7849 4.3% 1424 4.3% 13,886 4.0%
Labor market affiliation
Working 3068 19.6% 37,114 23.7% 3777 20.6% 47,291 25.8% 6845 20.1% 84,405 24.8%
Unemployed 228 1.5% 1862 1.2% 331 1.8% 2036 1.1% 559 1.6% 3898 1.1%
Retirement pension 12,029 76.8% 114,341 73.0% 13,864 75.5% 131,491 71.6% 25,893 76.1% 245,833 72.3%
Other 330 2.1% 3233 2.1% 390 2.1% 2801 1.5% 720 2.2% 6034 1.8%
Income
Low 3665 23.4% 31,606 20.2% 4374 23.8% 35,190 19.1% 8039 23.6% 66,796 19.6%
Middle 8745 55.9% 78,870 50.4% 10,085 54.9% 89,395 48.7% 18,830 55.4% 168,265 49.5%
High 3245 20.7% 46,074 29.4% 3903 21.3% 59,035 32.2% 7148 21.0% 105,109 30.9%
Charlson comorbidity index score
0 8874 56.7% 115,787 74.0% 9752 53.1% 124,259 67.7% 18,626 54.8% 240,046 70.6%
1 3544 22.6% 21,910 14.0% 4097 22.3% 29,464 16.0% 7641 22.5% 51,374 15.1%
≥2 3237 20.7% 18,853 12.0% 4513 24.6% 29,897 16.3% 7750 22.7% 48,750 14.3%
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patients and 88.4% of comparison subjects had one or more 
contacts to general practice (Table 2). The odds for having 
nine or more contacts were higher among lung cancers 
patients compared to comparison subjects (OR: 1.89 [95 
CI: 1.83–1.94]) (Table 2). Lung cancer patients had signifi-
cantly higher frequencies of GP contacts from four months 
prior to diagnosis and the differences rose consistently with 
a peak in the last month before diagnosis (Fig. 1A).
13.0% of the lung cancer patients and 3.3% of the 
comparisons had two or more radiographs performed 
during the 11 months before the last month before diag-
nosis (OR: 4.26 [95% CI: 4.08–4.45]) (Table 2). The rates 
were higher for lung cancer patients throughout all 
12 months before diagnosis with a large excess just before 
diagnosis (Fig. 1B).
7.4% of the lung cancer patients and 2.5% of com-
parison subjects had one or more first- time lung function 
test performed in general practice during the 11 months 
before diagnosis. During the 12 months before diagnosis 
the number of lung function test were significantly higher 
among lung cancer patients than among the comparisons 
(Fig. 1C) and the rates rose until peaking in the last 
month (IRR: 13.1 [95% CI: 12.2–14.2]).
During the last 11 months before the month before 
diagnosis, 20.8% of the lung cancer patients and 8.5% 
of the comparisons persons were treated with antibiotics 
twice or more (OR: 2.70 [95% CI: 2.61–2.78]) (Table 2). 
The higher number of antibiotic prescriptions was mainly 
seen in the last 4 months before diagnosis (Fig. 1E), dur-
ing month 12 to 6 prior to diagnosis lung cancer patients 
were treated less with antibiotics than compared to the 
comparison subjects.
Furthermore, 4.6% of the lung cancer cases and 1.4% 
of the comparisons had one or more new prescription 
of COPD medicine (Table 2).
Lung cancer patients with localized disease 
versus advanced disease
8, 7% of lung cancer patients with localized disease had 
no contacts in general practice compared to 6.9% of 
patients with advanced disease (OR: 0.74 [95% CI: 0.65–
0.83]) (Table 2) whereas the odds for having more contacts 
were similar between the two groups. 19.0% of patients 
with localized disease had two or more radiographs per-
formed during the 11 months before diagnosis compared 
to 11.6% of patients with advanced disease (OR = 0.54 
[95% CI: 0.50–0.59]). The use of lung function test in 
general practice and COPD prescriptions did not differ 
between patients with localized disease and patients with 
Table 2. Proportion of persons with consultations, lung function tests, radiographs, Antibiotics prescriptions, and COPD medicine prescriptions during 
months 12 to 1 prior to lung cancer diagnosis.
ALL study subjects All lung cancers
Lung cancer patients Comparison subjects OR (95%CI)1 Localized Metastatic OR (95% CI)2
Consultations
0 2507 7.4% 46399 13.6% 0.42 (0.39–0.44) 544 8.7% 1903 6.9% 0.74 (0.65–0.83)
1–4 6980 20.5% 98198 28.9% 0.68 (0.65–0.70) 1244 19.8% 5659 20.6% 0.99 (0.91–1.07)
5–8 6889 20.3% 72491 21.3% 0.98 (0.95–1.01) 1250 19.9% 5602 20.4% 1.00 (0.93–1.08)
≥9 17648 51.8% 123082 36.2% 1.89 (1.83–1.94) 3232 51.6% 14332 52.1% 1.09 (1.02–1.16)
Lung function tests
0 31500 92.6% 331855 97.5% 0.29 (0.27–0.30) 5787 92.3% 25473 92.6% 1.06 (0.94–1.18)
1 2342 6.9% 7778 2.3% 3.44 (3.26–3.63) 451 7.2% 1880 6.8% 0.94 (0.84–1.06)
≥2 175 0.5% 537 0.2% 3.74 (3.08–4.55) 32 0.5% 143 0.6% 1.00 (0.66–1.52)
Radiographs
0 23361 68.7% 300836 88.4% 0.28 (0.27–0.29) 3637 58.0% 19564 71.2% 1.89 (1.78–2.01)
1 6223 18.3% 28051 8.3% 2.43 (2.35–2.52) 1443 23.0% 4734 17.2% 0.70 (0.65–0.75)
≥2 4433 13.0% 11283 3.3% 4.26 (4.08–4.45) 1190 19.0% 3198 11.6% 0.54 (0.50–0.59)
Antibiotics
0 19410 57.1% 258900 76.1% 0.42 (0.41–0.43) 3345 53.4% 15919 57.9% 1.20 (1.13–1.28)
1 7527 22.1% 52412 15.4% 1.54 (1.50–1.59) 1486 23.6% 5991 21.8% 0.90 (0.84–0.97)
≥2 7080 20.8% 28858 8.5% 2.70 (2.61–2.78) 1439 23.0% 5586 20.3% 0.86 (0.80–0.92)
COPD prescriptions
0 32462 95.4% 335382 98.6% 0.30 (0.28–0.32) 5979 95.4% 26239 95.4% 1.01 (0.87–1.16)
≥1 1555 4.6% 4788 1.4% 3.33 (3.12–3.55) 291 4.6% 1257 4.6% 0.99 (0.86–1.15)
OR, odds ratio; CI, confidence interval; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease.
1Adjusted analyses comparing the activity between lung cancer patients and comparison subjects. 2Adjusted analyses comparing the activity between 
lung cancer patients with localized disease and lung cancer patients with metastatic disease. ORs are adjusted for age, county of origin, marital status, 
education, labor market affiliation, income, and comorbidity (CCI).
251 patients without information about stage at diagnosis are omitted.
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Figure 1. Contacts (A), X- rays (B), lung function tests (C), chronic obstructive pulmonary disease (COPD) prescriptions (D), and antibiotics prescriptions 
(E) in general practice. Upper part: Mean numbers of contacts, lung function test, X- rays, or prescriptions in general practice for lung cancer patients 
and matched comparison subjects prior to diagnosis/date with 95% confidence interval. Lower part: the incidence rate ratio (IRR) with 95% CIs.
A B
C D
E
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advanced disease, however, 23.0% of patients with local-
ized disease and 20.3% of patients with advanced disease 
had two or more prescriptions of antibiotics (OR: 0.86 
[95% CI: 0.80–0.92]).
Lung cancer patients with COPD versus 
other lung cancer patients
Lung cancer patients with COPD had more contacts in 
the 11  months prior to diagnosis than lung cancer 
patients without COPD (OR: 2.06 [95%CI: 1.93–2.19]) 
and they also had higher odds of having lung function 
tests performed. Lung cancer patients with COPD had 
more contacts (≥9: OR: 1.52 [95% CI: 1.43–1.62]), more 
lung function tests (≥2 OR: 3.23 [95% CI: 2.67–3.80]), 
more X- rays (≥2 OR: 2.23 [95% CI: 2.07–2.40]) and 
more prescriptions of antibiotics (≥2 OR: 1.93 [95% 
CI: 1.82–2.05]) than other COPD patients (Table  3). 
The difference in diagnostic activity was higher when 
comparing lung cancer patients and comparison subjects 
without COPD than when comparing lung cancer patients 
and comparisons diagnosed with COPD. 11% of lung 
cancer patients without COPD and 2.6% of comparisons 
without COPD had two or more X- rays performed 12 
to 1  months before diagnosis (OR: 4.19 [95% CI: 
3.98–4.41]).
In order to estimate the clinical relevance of the 
observed excess of general practice use we calculated 
risk estimates in the form of positive predictive values 
(PPVs). We calculated PPVs for having ≥9 contacts, ≥1 
lung function test, ≥2 X- rays, and ≥2 medicine prescrip-
tions, also stratified by COPD. All PPVs calculated were 
below 1% (0.3% for ≥9 contacts to 0.9% for ≥2 X- rays). 
These low PPVs are in range with many symptoms for 
lung cancer [11].
Discussion
This study, including 34,017 Danish lung cancer patients, 
found a higher frequency of contacts, diagnostic tests, 
and prescriptions in general practice for lung cancer patients 
compared with a comparison group, with a steep increase 
before the month prior to diagnosis. There was no impor-
tant difference in activity when dividing the lung cancer 
patients into localized and advanced disease at diagnosis 
which indicates that they might present with similar symp-
toms although patients with advanced lung cancer had 
fewer radiographs before diagnosis than patients with local 
cancers. When dividing the study group according to 
COPD, the difference in activity between lung cancer 
patients and comparisons where more pronounced in the 
group without COPD. This indicates that having COPD 
can mask symptoms of lung cancer.
Strengths and limitations
The strength of this study was a high statistical precision 
owing to the large, national study population. All data 
were collected from nationwide Danish registers. Cancer 
patient data were included from The Danish Cancer Registry 
and the Danish Lung Cancer Registry in order to have 
an almost complete inclusion of patients and clinical data 
[15–17]. The information on healthcare services provided 
in primary care is considered to be valid as registration 
of these services forms the basis for remuneration of the 
GPs [17]. By matching lung cancer patients and com-
parison persons according to age, gender, and general 
practice we diminished the risk of confounding. However, 
the results may have been influenced by confounding by 
smoking as we were not able to obtain smoking history, 
and there may be residual confounding by comorbidity 
as CCI does not include diseases managed only in general 
practice.
In the analyses of general practice activity we omitted 
the last month before diagnosis to eliminate the inevitable 
increase in activity just before diagnosis. Furthermore, 
we omitted patients’ lung function tests and prescriptions 
if they had such tests in the months between 12 and 36 
before diagnosis. Test and prescriptions included in the 
analyses where therefore first- time, reflecting the GPs 
response to the symptoms of the patients seen in practice 
at that time. Thus we predominantly explored new epi-
sodes of symptoms or signs where the GPs response 
would be a lung function test or prescription of 
medicine.
A limitation of the study was the lack of information 
on other lung diseases such as asthma, these diseases 
will increase GP contact rate and would probably be 
uneven distributed with a higher incidence among patients 
with lung cancer. However, a large proportion of these 
patients would have been in an ongoing follow- up for 
the disease and they would have had lung function tests 
and prescriptions for medication in years before diagnosis. 
These tests would therefore have been omitted in the 
analyses. A further limitation of this study was a lack 
of information on the reasons for the consultations with 
the GPs.
We restricted our analyses to first occurrence of cancer 
to avoid the influence of an increased awareness of the 
GP among patients with a history of cancer. Being popu-
lation based and thus including all lung cancer patients 
make the findings generalizable to other relevant health 
care systems.
Excess consultations among the lung cancer patients 
was also found in Danish study mapping the routes to 
diagnosis of lung cancer patients [12] and a UK study 
of consultations before diagnosis [28].
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The fact that lung cancer patients are seen in general 
practice before diagnosis and that the GP acts on the 
contacts with a high range of treatment and diagnostic 
activity months before diagnosis (even when omitting the 
last month) can be based on two things (or both things 
combined); either the GPs suspects cancer but fails to 
make the one diagnostic test to find the cancer (or fails 
to refer timely to fast- track) or the GP do not suspect 
cancer by interpreting the symptoms as something else. 
The latter is supported by the increased use of lung func-
tion tests, antibiotics, and COPD medication. A Danish 
study found that comorbidity delayed diagnosis in around 
23% of lung cancer patients seen by GPs [29]. Symptoms 
like cough, weight loss, or breathlessness may be ascribed 
to known comorbidity rather than lung cancer. This is 
in line with our findings.
Many of the lung cancer patients had two or more 
X- rays performed prior to diagnosis which is in line with 
results from a Danish study mapping the routes to diag-
nosis [12]. For patients with localized disease this excess 
of X- rays was more pronounced. This could be based on 
false negative X- rays which occur in as much as a quarter 
of cancer patients [30, 31].
Patients with advanced disease had more contacts to 
general practice than patients with localized disease. This 
could be patients, with localized disease, bypassing general 
practice, and getting the diagnosis in connection with a 
hospital inpatients visit for other diseases and thus having 
an earlier lung cancer diagnosis.
We found virtually no difference in activity between 
patients with localized disease and advanced disease. A 
British study from 2015 found no difference in symptoms 
presented in general practice according to stage at diag-
nosis [32]. However, the difference we did find (more 
X- rays in the group of patients with localized disease) 
may be rooted in the X- rays poor sensitivity, especially 
for small tumors.
The results, on the other hand, indicate an opportunity 
to optimize the early detection of lung cancer in general 
practice. So the question remains, how to select patients 
for further examination. GP awareness could be relevant 
as a Danish study from 2014 suggests that providing GPs 
with a short update on lung cancer (early symptoms, how 
to refer timely) would make the GPs refer more patients 
to examinations [33]. Earlier and faster diagnosis may also 
be achieved by granting GPs free, direct access to low- dose 
computed tomography; this would provide them with a 
more sensitive test for lung cancer than the X- rays.
Conclusion
The findings of this large population- based study revealed 
an increase in healthcare seeking and diagnostic activity 
in general practice among lung cancer patients prior to 
their diagnosis. This was not modified by the stage of 
the cancer but by whether the patients had COPD or 
not. Overall, the results indicate that a “diagnostic time 
window” is present, in which there is opportunity to 
diagnose lung cancer more timely in general practice. The 
high number of repeated X- rays, lung function tests, and 
prescription of lung medicine and antibiotics show that 
GPs start investigating the patient’s months before the 
diagnosis. The results support Continuing Medical 
Education for GPs and indicate a need for more studies 
on how to select patients for further diagnostic test and 
which test may be the most optimal in general 
practice.
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